Marksans Pharma shares surged 13.13% to ₹249.19 following the company's impressive quarterly earnings performance. According to reports from Business Standard, the pharmaceutical company delivered robust financial results that exceeded market expectations, driving investor confidence in the stock.
On a consolidated basis, Marksans Pharma reported a net profit of ₹148.13 crore in Q4 FY26, representing a remarkable 63.59% year-on-year growth and 30.85% quarter-on-quarter increase. As reported by Business Standard, revenue from operations rose 20.84% YoY to ₹856.11 crore in Q4 FY26, while increasing 13.48% QoQ. The company's gross profit stood at ₹465.5 crore, up 21.5% YoY and 6.2% QoQ, with gross margin improving to 54.4% from 54.1% in Q4 FY25. The robust operational growth was further supported by a more than twofold increase in other income to ₹35.2 crore, which trickled down to the bottom line despite a doubling of tax expenses to ₹51 crore.
According to Business Standard, EBITDA stood at ₹195.4 crore in Q4 FY26, up 54% YoY and 21.6% QoQ. The EBITDA margin expanded sharply to 22.8% from 17.9% in the year-ago period and 21.3% in Q3 FY26**, aided by operating leverage and tight cost controls. Profit before tax reached ₹199.99 crore, up 72.27% YoY and 32.78% QoQ. However, raw material costs increased 40.89% YoY to ₹264.97 crore, while employee expenses rose 9.81% YoY to ₹106.75 crore.
As reported by Business Standard, the company's quarterly growth was driven by new launches in Australia and the UK, with price erosion in the UK market stabilizing during the quarter. Marksans Pharma launched its first Rx branded products in Australia during Q4 FY26. Australia and New Zealand revenues grew 61% YoY, while the US and North America business increased 24% YoY, supported by traction from new product launches and expansion across OTC store brands.
For the full year FY26, Marksans Pharma reported net profit of ₹417.90 crore, up 9.81% YoY, while revenue increased 12.51% YoY to ₹2,950.94 crore. According to Business Standard, EBITDA for FY26 stood at ₹600.8 crore, up 12.8% YoY, with EBITDA margin improving marginally to 20.4% from 20.3% in FY25. The company reported net cash flow from operating activities of ₹458.12 crore in FY26, significantly improved from ₹206.66 crore in FY25, with a cash balance of ₹990 crore as of March 31, 2026. The board recommended a final dividend of ₹0.90 per equity share for FY26.
